Targeted Co-delivery of Tumor Antigen and α-Galactosylceramide to CD141+ Dendritic Cells Induces a Potent Tumor Antigen-Specific Human CD8+ T Cell Response in Human Immune System Mice - Archive ouverte HAL Access content directly
Journal Articles Frontiers in Immunology Year : 2020

Targeted Co-delivery of Tumor Antigen and α-Galactosylceramide to CD141+ Dendritic Cells Induces a Potent Tumor Antigen-Specific Human CD8+ T Cell Response in Human Immune System Mice

(1, 2) , (3) , (4) , (1, 5) , (1, 2) , (4) , (3) , (1) , (3) , (6) , (4) , (1, 2)
1
2
3
4
5
6

Abstract

Active co-delivery of tumor antigens (Ag) and α-galactosylceramide (α-GalCer), a potent agonist for invariant Natural Killer T (iNKT) cells, to cross-priming CD8α+ dendritic cells (DCs) was previously shown to promote strong anti-tumor responses in mice. Here, we designed a nanoparticle-based vaccine able to target human CD141+ (BDCA3+) DCs - the equivalent of murine CD8α+ DCs - and deliver both tumor Ag (Melan A) and α-GalCer. This nanovaccine was inoculated into humanized mice that mimic the human immune system (HIS) and possess functional iNKT cells and CD8+ T cells, called HIS-CD8/NKT mice. We found that multiple immunizations of HIS-CD8/NKT mice with the nanovaccine resulted in the activation and/or expansion of human CD141+ DCs and iNKT cells and ultimately elicited a potent Melan-A-specific CD8+ T cell response, as determined by tetramer staining and ELISpot assay. Single-cell proteomics further detailed the highly polyfunctional CD8+ T cells induced by the nanovaccine and revealed their predictive potential for vaccine potency. This finding demonstrates for the first time the unique ability of human iNKT cells to license cross-priming DCs in vivo and adds a new dimension to the current strategy of cancer vaccine development.
Fichier principal
Vignette du fichier
fimmu-11-02043.pdf (1.62 Mo) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Loading...

Dates and versions

inserm-02960071 , version 1 (07-10-2020)

Licence

Attribution - CC BY 4.0

Identifiers

Cite

Jing Huang, Jing Zhou, Reem Ghinnagow, Toshiyuki Seki, Sho Iketani, et al.. Targeted Co-delivery of Tumor Antigen and α-Galactosylceramide to CD141+ Dendritic Cells Induces a Potent Tumor Antigen-Specific Human CD8+ T Cell Response in Human Immune System Mice. Frontiers in Immunology, 2020, 11, pp.2043. ⟨10.3389/fimmu.2020.02043⟩. ⟨inserm-02960071⟩
141 View
38 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More